Ontology highlight
ABSTRACT:
SUBMITTER: Yamakawa H
PROVIDER: S-EPMC8161027 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
Yamakawa Hirofumi H Setoguchi Shuichi S Goto Shotaro S Watase Daisuke D Terada Kazuki K Nagata-Akaho Nami N Toki Erina E Koga Mitsuhisa M Matsunaga Kazuhisa K Karube Yoshiharu Y Takata Jiro J
Pharmaceutics 20210520 5
The first-choice drug for acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA), frequently causes drug-resistance and some adverse effects. Thus, an effective and safe agent for ATRA-resistant APL is needed. Menaquinone-4 (MK-4, vitamin K<sub>2(20)</sub>), used for osteoporosis treatment, does not have serious adverse effects. It has been reported that MK-4 has growth-inhibitory effects on HL60 cells by inducing apoptosis via the activation of Bcl-2 antagonist killer 1 (BAK). Howev ...[more]